Compare PAGSEG Inc (PAGS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PAGSEG Inc vs Sana Biotechnology Inc — how do they compare? PAGSEG Inc trades at $11.16 (market cap $2.94B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: PAGSEG Inc is far larger — about 3.5× Sana Biotechnology Inc's market cap, and PAGSEG Inc pays a 10.49% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold PAGSEG Inc for 26 Days and Sana Biotechnology Inc for 23 Days on average.
| PAGS | SANA | |
|---|---|---|
Market Cap | $2.94B | $836.71M |
Volume | 4,242,708 | 4,507,444 |
Sector | Industrials | Health |
52-Week High | $12.00 | $5.92 |
52-Week Low | $8.44 | $2.68 |
Typical Hold Time | 26 Days | 23 Days |
Enterprise Value | $11.02B | $749.96M |
Dividend Yield | 10.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PAGS trades at $11.16, up 6.18% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 7.1 and net income margin of 10.45%. Recent Q2 2026 earnings beat expectations at $0.41 per share. The company maintains a dividend yield with a $0.28 payment scheduled for September 2026. Revenue growth remains stable at $20.6B for 2026 with improving profitability.
PAGS presents a compelling value opportunity with attractive valuation multiples and consistent earnings performance. Key risks include competitive pressures in digital banking and macroeconomic sensitivity in Brazil. Analyst consensus is strongly bullish with 15 buy ratings and a $10.70 price target, though the current price exceeds this target, suggesting potential near-term consolidation.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
